Resources
11 Results (showing 1 - 10)
Results sorted by updated date (newest first)
Results sorted by updated date (newest first)
Posted 3/25/2021 (updated 4/5/2024)
Stimulants 2021: An Update—Clinical Issues and Treatments
The presenter will review considerations in engaging and treating individuals with stimulant use disorders and present evidence-based treatment strategies relevant to rural communities addressing this growing problem.
Posted 3/25/2021 (updated 4/5/2024)
Effective Harm Reduction Strategies for People Who Actively Use Opioids and/or Psychostimulants
Participants will learn evidenced-based harm reduction strategies to keep people who use opioids and psychostimulants alive with reduced disease burden. Presenters will discuss methods of engaging people who actively use opioids and/or psychostimulants, harm reduction interventions, overdose prevention and response, overamping prevention and response, and linkages to care.
Posted 2/24/2021 (updated 4/4/2024)
This webinar provided new information on the risks and clinical challenges presented by individuals who use psychostimulants (cocaine, methamphetamine and prescription stimulants). A review of the clinical strategies that are important in working with this population were presented, including psychosocial and medication treatments for those with stimulant use disorder. Presented by Richard Rawson, Ph.D.
Posted 10/20/2021 (updated 4/3/2024)
Background As the opioid overdose crisis persists and take-home naloxone (THN) programmes expand, it is important that the intervention is targeted towards those most likely to use it. We examined THN program participants to 1) describe those that return for refills, specifically those that reported multiple use (supersavers) and 2) to determine what rescuer characteristics were associated with higher rates of THN use.
Methods This study included a cohort of consenting THN recipients from June 2014- June 2021 who completed initial and refill questionnaires from a widespread program in Norway. Adjusted logistic regression was used to explore associations with higher rates of THN use. ‘Super-savers’ reported three or more THN uses.
Posted 10/14/2021 (updated 4/3/2024)
Stimulant intoxication, withdrawal, and psychosis have accepted and established treatment strategies. Several lifesaving harm reduction interventions/services are available. There are no Food and Drug Administration-approved medications for treatment of stimulant use disorder, although several are promising. Behavioral treatment, especially the use of contingency management (and other approaches with supportive evidence), has by far the best evidence of effectiveness. The presenter reviewed topics of importance to clinicians treating individuals with stimulant use disorder.
Rick Rawson, PhD, University of Vermont Rural Center of Excellence
Posted 10/14/2021 (updated 4/3/2024)
Participants learned evidenced-based harm reduction strategies to keep people who use opioids and psychostimulants alive with reduced disease burden. Presenters discussed methods of engaging people who actively use opioids and/or psychostimulants, harm reduction interventions, overdose prevention and response, overamping prevention and response, and linkages to care.
Robert Childs, MPH, JBS International
Christine Rodriguez, MPH, Vital Strategies
Posted 12/15/2020 (updated 4/3/2024)
Participants learned evidenced based harm reduction strategies to keep people who use drugs (PWUD) alive with reduced disease burden. Presenters discussed methods of engaging PWUD, linkages to MOUD, behavioral health and recovery supports for individuals ready for these supports
Posted 8/4/2021 (updated 4/2/2024)
Posted 8/4/2021 (updated 4/2/2024)
Posted 7/31/2023 (updated 3/26/2024)
This presentation will cover health equity regarding rural American Indian and Alaska Native (AI/AN) communities' prevention and treatment efforts to address substance use disorder (SUD), including the need for contingency management for stimulants.